Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma

NCT ID: NCT03500445

Last Updated: 2025-10-03

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 75 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-02-13
• Study Completion Date: 2026-06-30

Brief Summary

The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.

Conditions

Myeloma; Multiple Myeloma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment Arm (D-KRd)

Group Type: EXPERIMENTAL

Daratumumab

Intervention Type: DRUG

Daratumumab (16 mg/kg) will be administered as an IV infusion:

• Cycle 1-2: 16 mg/kg weekly
• Cycles 3-8: 16 mg/kg IV infusion every 2 weeks
• Cycles 9-24: 16 mg/kg IV infusion Day 1

Carfilzomib

Intervention Type: DRUG

Carfilzomib will be given as an IV infusion over 30 minutes:

• Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8, 9 of cycle 1) will be allowed at the treating physician's discretion.
• Cycle 2-9: 36 mg/m2 (or best tolerated dose) Days 1, 2, 8, 9, 15 and 16
• Cycles 9-24: 36 mg/m2 (or best tolerated dose) Days 1, 2, 15 and 16

Lenalidomide

Intervention Type: DRUG

Lenalidomide will be taken orally as follows:

• Cycles 1-24: 25 mg (or best tolerated dose) PO Days 1-21

Dexamethasone

Intervention Type: DRUG

Dexamethasone will be administered prior to carfilzomib (on days that they coincide), as follows:

• Cycles 1-9: 40 mg PO (subjects ≤ 75 years) or 20 mg PO (subjects ≥ 75 years) per week
• Cycles 9-24: 20 mg PO per week

During weeks when daratumumab is given: 40 mg dexamethasone weekly, 20 mg prior to daratumumab infusion and 20 mg PO the day after

During weeks with no daratumumab, single dose of 20 mg on day 1

Interventions

Daratumumab

Daratumumab (16 mg/kg) will be administered as an IV infusion:

• Cycle 1-2: 16 mg/kg weekly
• Cycles 3-8: 16 mg/kg IV infusion every 2 weeks
• Cycles 9-24: 16 mg/kg IV infusion Day 1

Intervention Type: DRUG

Carfilzomib

Carfilzomib will be given as an IV infusion over 30 minutes:

• Cycle 1: 20 mg/m2 Days 1, 2; 36 mg/m2 Days 8, 9, 15, 16. Alternatively, intermediate dose escalation (to 27mg/m2 on days 8, 9 of cycle 1) will be allowed at the treating physician's discretion.
• Cycle 2-9: 36 mg/m2 (or best tolerated dose) Days 1, 2, 8, 9, 15 and 16
• Cycles 9-24: 36 mg/m2 (or best tolerated dose) Days 1, 2, 15 and 16

Intervention Type: DRUG

Lenalidomide

Lenalidomide will be taken orally as follows:

• Cycles 1-24: 25 mg (or best tolerated dose) PO Days 1-21

Intervention Type: DRUG

Dexamethasone

Dexamethasone will be administered prior to carfilzomib (on days that they coincide), as follows:

• Cycles 1-9: 40 mg PO (subjects ≤ 75 years) or 20 mg PO (subjects ≥ 75 years) per week
• Cycles 9-24: 20 mg PO per week

During weeks when daratumumab is given: 40 mg dexamethasone weekly, 20 mg prior to daratumumab infusion and 20 mg PO the day after

During weeks with no daratumumab, single dose of 20 mg on day 1

Intervention Type: DRUG

Other Intervention Names

DARZALEX®; KYPROLIS®; REVLIMID®

Eligibility Criteria

Inclusion Criteria

• Newly diagnosed, previously untreated myeloma requiring systemic chemotherapy

• Prior treatment of hypercalcemia or spinal cord compression or active and/or aggressively progressing myeloma with corticosteroids or lenalidomide or bortezomib-based regimens does not disqualify the patient (the treatment dose should not exceed the equivalent of 160 mg of dexamethasone in a 4 week period or not more than 1 cycle of Proteasome Inhibitor / Immunomodulatory-based therapy)
• Both transplant and non-transplant candidates are eligible.
• Diagnosis of symptomatic multiple myeloma as per current International Myeloma Working Group (IMWG) uniform criteria prior to initial treatment
• Monoclonal plasma cells in the Bone Marrow (BM) ≥ 10% or presence of a biopsy-proven plasmacytoma
• Measurable disease, prior to initial treatment as indicated by one or more of the following:

• Serum M-protein ≥ 1 g/dL
• Urine M-protein ≥ 200 mg/24 hours
• If serum protein electrophoresis is felt to be unreliable for routine M-protein measurement, then quantitative immunoglobulin levels are acceptable
• Serum freelite measurable disease as per current IMWG criteria
• Bone marrow specimen will be required at study entry; available DNA sample from pre-induction BM will be used for calibration step for MRD evaluation by gene sequencing.
• Males and females ≥ 18 years of age
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Adequate hepatic function, with bilirubin ≤ 1.5 x upper limit of normal (ULN) and aspirate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 x ULN
• Absolute Neutrophil Count (ANC) ≥ 1.0 x 109/L, hemoglobin ≥ 8 g/dL, platelet count ≥ 75 x 109/L.
• Calculated creatinine clearance (by Cockroft-Gault) ≥ 50 mL/min or serum creatinine below 2 g/dL
• Woman of childbearing potential must have 2 negative pregnancy tests prior to initiating lenalidomide.
• Woman of childbearing potential must agree to use 2 reliable forms of contraception simultaneously or to practice complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) for at least 28 days before starting lenalidomide; 2) while participating in the study; and 3) for at least 30 days after discontinuation from the study.
• Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 90 days following discontinuation from the study even if he has undergone a successful vasectomy.
• All study participants in the US must be consented to and registered into the mandatory Revlimid Risk Evaluation and Mitigation Strategy (REMS®) program and be willing and able to comply with the requirements of Revlimid REMS®.
• Voluntary written informed consent.

Exclusion Criteria

• Frail non-transplant candidates, defined as in Palumbo et al, Blood 2015.
• Non-secretory or hyposecretory multiple myeloma, prior to initial treatment defined as <1.0 g/dL M-protein in serum, <200 mg/24 hr urine M-protein, and no measurable disease as per IMWG by Freelite.
• POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes)
• Amyloidosis
• Plasma cell leukemia
• Waldenström's macroglobulinemia or Immunoglobulin M-producing (IgM) myeloma
• Radiotherapy to multiple sites or immunotherapy within 4 weeks before start of protocol treatment (localized radiotherapy to a single site at least 1 week before start is permissible)
• Participation in an investigational therapeutic study within 3 weeks or within 5 drug half-lives (t1/2) prior to first dose, whichever time is greater
• Potential subjects with evidence of progressive disease as per IMWG criteria
• Patients not able to tolerate daratumumab, carfilzomib, lenalidomide or dexamethasone
• Peripheral neuropathy ≥ Grade 2 at screening
• Diarrhea > Grade 1 in the absence of antidiarrheals
• Central Nervous System (CNS) involvement
• Pregnant or lactating females
• Major surgery within 3 weeks prior to first dose.
• Myocardial infarction within 6 months prior to enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
• Prior or concurrent pulmonary embolism
• Known moderate or severe persistent asthma or known chronic obstructive pulmonary disease (COPD)

• Known or suspected chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal
• Moderate or severe persistent asthma within the past 2 years, or currently has uncontrolled asthma of any classification. Note that subjects who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study.
• Rate-corrected QT interval of electrocardiograph (QTc) > 470 msec on a 12-lead ECG during screening
• Uncontrolled hypertension or diabetes
• Acute infection requiring systemic antibiotics, antivirals, or antifungals within two weeks prior to first dose
• Known seropositive for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
• Non-hematologic malignancy or non-myeloma hematologic malignancy within the past 3 years except a) adequately treated basal cell, squamous cell skin cancer, thyroid cancer, carcinoma in situ of the cervix, or prostate cancer < Gleason Grade 6 with stable prostate specific antigen levels or cancer considered cured by surgical resection alone
• Any clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Janssen Scientific Affairs, LLC

INDUSTRY

Sponsor Role: collaborator

Amgen

INDUSTRY

Sponsor Role: collaborator

University of Chicago

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andrzej Jakubowiak, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Chicago

Locations

The University of Chicago

Chicago, Illinois, United States

Countries

United States

Other Identifiers

IRB17-1097

Identifier Type: -

Identifier Source: org_study_id